Literature DB >> 23871824

Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis.

Stéphane Verguet1, Shane Murphy, Benjamin Anderson, Kjell Arne Johansson, Roger Glass, Richard Rheingans.   

Abstract

BACKGROUND: An estimated 4% of global child deaths (approximately 300,000 deaths) were attributed to rotavirus in 2010. About a third of these deaths occurred in India and Ethiopia. Public finance of rotavirus vaccination in these two countries could substantially decrease child mortality and also reduce rotavirus-related hospitalizations, prevent health-related impoverishment and bring significant cost savings to households.
METHODS: We use a methodology of 'extended cost-effectiveness analysis' (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. We measure program impact along four dimensions: 1) rotavirus deaths averted; 2) household expenditures averted; 3) financial risk protection afforded; 4) distributional consequences across the wealth strata of the country populations.
RESULTS: In India and Ethiopia, the program would lead to a substantial decrease in rotavirus deaths, mainly among the poorer; it would reduce household expenditures across all income groups and it would effectively provide financial risk protection, mostly concentrated among the poorest. Potential indirect benefits of vaccination (herd immunity) would increase program benefits among all income groups, whereas potentially decreased vaccine efficacy among poorer households would reduce the equity benefits of the program.
CONCLUSIONS: Our approach incorporates financial risk protection and distributional consequences into the systematic economic evaluation of vaccine policy, illustrated here with the case study of public finance for rotavirus vaccination. This enables selection of vaccine packages based on the quantitative inclusion of information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine policy, in addition to how much health is being bought.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Child health; Equity; Extended cost-effectiveness analysis (ECEA); Financial risk protection; Low- and middle-income settings; Rotavirus; Vaccination

Mesh:

Substances:

Year:  2013        PMID: 23871824     DOI: 10.1016/j.vaccine.2013.07.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

Review 1.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

2.  Facilitators and barriers for use of rotavirus vaccine amongst various stakeholders and its implications for Indian context - A systematic review.

Authors:  Aditi Apte; Sudipto Roy; Ashish Bavdekar; Sanjay Juvekar; Siddhivinayak Hirve
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

Review 3.  Valuing vaccination.

Authors:  Till Bärnighausen; David E Bloom; Elizabeth T Cafiero-Fonseca; Jennifer Carroll O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

Review 4.  Systematic review of the economic value of diarrheal vaccines.

Authors:  Richard Rheingans; Mirna Amaya; John D Anderson; Poulomy Chakraborty; Jacob Atem
Journal:  Hum Vaccin Immunother       Date:  2014-05-27       Impact factor: 3.452

5.  Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.

Authors:  Thomas Ward; Ruben E Mujica-Mota; Anne E Spencer; Antonieta Medina-Lara
Journal:  Pharmacoeconomics       Date:  2021-10-29       Impact factor: 4.981

6.  COVID-19 Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Cost-Benefit Analysis.

Authors:  Mario Cesare Nurchis; Alberto Lontano; Domenico Pascucci; Martina Sapienza; Eleonora Marziali; Francesco Castrini; Rosaria Messina; Luca Regazzi; Francesco Andrea Causio; Andrea Di Pilla; Giuseppe Vetrugno; Gianfranco Damiani; Patrizia Laurenti
Journal:  Int J Environ Res Public Health       Date:  2022-06-26       Impact factor: 4.614

7.  Household catastrophic healthcare expenditure and impoverishment due to rotavirus gastroenteritis requiring hospitalization in Malaysia.

Authors:  Tharani Loganathan; Way-Seah Lee; Kok-Foo Lee; Mark Jit; Chiu-Wan Ng
Journal:  PLoS One       Date:  2015-05-05       Impact factor: 3.240

8.  Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso.

Authors:  Anaïs Colombini; Caroline Trotter; Yvette Madrid; Andromachi Karachaliou; Marie-Pierre Preziosi
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

9.  Economic evaluation of point-of-care testing and treatment for sexually transmitted and genital infections in pregnancy in low- and middle-income countries: A systematic review.

Authors:  Olga P M Saweri; Neha Batura; Rabiah Al Adawiyah; Louise M Causer; William S Pomat; Andrew J Vallely; Virginia Wiseman
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

Review 10.  The broader economic impact of vaccination: reviewing and appraising the strength of evidence.

Authors:  Mark Jit; Raymond Hutubessy; May Ee Png; Neisha Sundaram; Jananie Audimulam; Safiyah Salim; Joanne Yoong
Journal:  BMC Med       Date:  2015-09-03       Impact factor: 11.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.